TY  - JOUR
AU  - Aygören-Pürsün, Emel
AU  - Bygum, Anette
AU  - Grivcheva-Panovska, Vesna
AU  - Magerl, Markus
AU  - Graff, Jochen
AU  - Steiner, Urs C
AU  - Fain, Olivier
AU  - Huissoon, Aarnoud
AU  - Kinaciyan, Tamar
AU  - Farkas, Henriette
AU  - Lleonart, Ramon
AU  - Longhurst, Hilary J
AU  - Rae, William
AU  - Triggiani, Massimo
AU  - Aberer, Werner
AU  - Cancian, Mauro
AU  - Zanichelli, Andrea
AU  - Smith, William B
AU  - Baeza, Maria L
AU  - Du-Thanh, Aurelie
AU  - Gompels, Mark
AU  - Gonzalez-Quevedo, Teresa
AU  - Greve, Jens
AU  - Guilarte, Mar
AU  - Katelaris, Constance
AU  - Dobo, Sylvia
AU  - Cornpropst, Melanie
AU  - Clemons, Desiree
AU  - Fang, Lei
AU  - Collis, Phil
AU  - Sheridan, William
AU  - Maurer, Marcus
AU  - Cicardi, Marco
PY  - 2018
DO  - 10.1056/NEJMoa1716995
UR  - http://hdl.handle.net/10668/12755
T2  - The New England journal of medicine
AB  - Hereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade. BCX7353 is a potent oral small-molecule...
LA  - en
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Angioedemas, Hereditary
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Enzyme Inhibitors
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Plasma Kallikrein
KW  - Quality of Life
TI  - Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
TY  - research article
VL  - 379
ER  -